NervGen Pharma

NervGen Pharma FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of NervGen Pharma (NGEN.V) as of Oct 18, 2026 is 44.20 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 70.15 % — a change of -37.00% (lower).

FCF Conversion

44.20 %

YoY

-37.00%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of NervGen Pharma is 2025 44.20 % . FCF Conversion Rate (FCF/EBITDA) of NervGen Pharma was 2024 70.15 % . It decreases by -37.00% lower compared to the previous year.

The NervGen Pharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
76.56 CAD
Jan 1, 2019
82.88 CAD
Jan 1, 2020
56.41 CAD
Jan 1, 2021
65.00 CAD
Jan 1, 2022
85.92 CAD
Jan 1, 2023
50.49 CAD
Jan 1, 2024
70.15 CAD
Jan 1, 2025
44.20 CAD
The NervGen Pharma FCF Conversion history
YEARFCF ConversionYoY
44.20 %-37.00%
70.15 %+38.94%
50.49 %-41.24%
85.92 %+32.20%
65.00 %+15.22%
56.41 %-31.94%
82.88 %+8.26%
76.56 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

NervGen Pharma Stock analysis

What does NervGen Pharma do? NervGen Pharma Corp, based in Vancouver, Canada, operates in the Health Care sector as a regenerative medicine company. It focuses on discovering, developing, and commercializing therapeutics for nerve damage, including spinal cord and peripheral nerve injuries. The company is advancing its lead compound NVG-291 for spinal cord injury, Alzheimer’s disease, and multiple sclerosis. With 10 full-time employees, it has two wholly owned subsidiaries, NervGen US Inc. and NervGen Australia Pty Ltd. NervGen Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NervGen Pharma stock

FCF Conversion Rate (FCF/EBITDA) of NervGen Pharma is 44.20 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of NervGen Pharma changed from 70.15 % to 44.20 %, representing a -37.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) NervGen Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s NervGen Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — NervGen Pharma

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — NervGen Pharma